Looking for reliable information about interstitial lung disease (ILD) & scleroderma? Visit our newly updated webpage. 🫁 ILD is a serious complication of systemic sclerosis that can cause inflammation and...
Read More
The 5th Annual ILD Day is coming up on September 10: mark your calendar for these opportunities to learn and get involved! Interstitial lung disease (ILD) is a group of...
Read More
ILD Day is coming up! Join us in raising awareness about interstitial lung disease (ILD) and supporting people who live with this living with this lung condition alongside scleroderma. There...
Read More
Living with scleroderma? Learn about its impact on the lungs at our upcoming webinar. 🫁 Join us for a special ILD Day webinar in recognition of Interstitial Lung Disease (ILD)...
Read More
Registration opens soon for a special ILD-focused webinar, taking place on Tuesday, September 16, 2025, at 9:00 AM PT / 12:00 PM ET. Led by Dr. Toby Maher, Professor of...
Read More
Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains...
Read More
We are excited to share that CONQUEST, a global platform clinical trial created by the Scleroderma Research Foundation, has opened 68 sites in 13 countries. Individuals with interstitial lung disease...
Read More
Groundbreaking clinical study recently launched to accelerate clinical development of new treatments for scleroderma Journal of Scleroderma and Related Disorders outlines protocol and rationale for two initial investigational drugs San...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
• Sanofi is inaugural partner • Initial focus on Interstitial Lung Disease Secondary to Scleroderma • SRF will submit and hold the IND as the trial Sponsor SAN FRANCISCO, August...
Read More
